PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
48.17
+2.90 (6.41%)
Aug 13, 2025, 4:00 PM - Market closed
ANSYS Employees
PTC Therapeutics had 939 employees as of December 31, 2024. The number of employees decreased by 116 or -11.00% compared to the previous year.
Employees
939
Change (1Y)
-116
Growth (1Y)
-11.00%
Revenue / Employee
$1,879,584
Profits / Employee
$670,046
Market Cap
3.83B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 939 | -116 | -11.00% |
Dec 31, 2023 | 1,055 | -355 | -25.18% |
Dec 31, 2022 | 1,410 | 233 | 19.80% |
Dec 31, 2021 | 1,177 | 210 | 21.72% |
Dec 31, 2020 | 967 | 206 | 27.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PTCT News
- 5 days ago - PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 15 days ago - Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics - Benzinga
- 15 days ago - These Analysts Increase Their Forecasts On PTC Therapeutics - Benzinga
- 16 days ago - US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters
- 16 days ago - PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - PRNewsWire
- 23 days ago - PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire